Bevacizumab (Avastin) as Adjuvant in Newly Diagnosed Glioblastoma Fails to Improve Survival
University of Maryland Medical CenterAdding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with glioblastoma, a very aggressive form of brain cancer, researchers have found. The results of the large, multicenter study are being presented today at the American Society of Clinical Oncology (ASCO) annual meeting.